SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P80
Within normal range
vs 2Y Ago
2.9x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 19.89% |
| Q3 2025 | 27.89% |
| Q2 2025 | -8.37% |
| Q1 2025 | 0.07% |
| Q4 2024 | -2.56% |
| Q3 2024 | 15.15% |
| Q2 2024 | -16.30% |
| Q1 2024 | 89.07% |
| Q4 2023 | 6.89% |
| Q3 2023 | 10.48% |
| Q2 2023 | -19.34% |
| Q1 2023 | -36.80% |
| Q4 2022 | -2.59% |
| Q3 2022 | -14.63% |
| Q2 2022 | -35.57% |
| Q1 2022 | 25.14% |
| Q4 2021 | -29.15% |
| Q3 2021 | -19.56% |
| Q2 2021 | 46.17% |
| Q1 2021 | -16.50% |
| Q4 2020 | 0.00% |